Systematic mutagenesis of oncocin reveals enhanced activity and insights into the mechanisms of antimicrobial activity

ORAL

Abstract

Oncocin is a proline-rich antimicrobial peptide that inhibits protein synthesis by binding to the bacterial ribosome. The aim of this work is to improve the antimicrobial activity of oncocin by systematic peptide mutagenesis and activity evaluation. We discovered that a pair of cationic substitutions (P4K and P7K/R) enhanced the activity by 2 to 4 fold (p<0.05) against multiple Gram-negative bacteria. An in vitro transcription / translation assay indicated that the increased activity was not because of stronger ribosome binding. Instead a cellular internalization assay revealed a higher internalization rate for the optimized analogs thereby suggesting a mechanism to increase potency. In addition, we found that the optimized peptides' benefit is dependent upon nutrient-depleted media conditions.

*This work was supported by grants from the National Institutes of Health (R01GM121777 and R01GM111358) and by a grant from the National Science Foundation (CBET-1412283). We acknowledge computational support from the Minnesota Supercomputing Institute and from the Extreme Science and Engineering Discovery Environment, which is supported by National Science Foundation ACI-10535753.

Presenters

  • Pin-Kuang Lai

    • University of Minnesota

Authors

  • Pin-Kuang Lai

    • University of Minnesota
  • Kathryn Geldart

    • University of Minnesota
  • Seth Ritter

    • University of Minnesota
  • yiannis kaznessis

    • University of Minnesota
  • Benjamin Hackel

    • University of Minnesota